Search Results 1781-1790 of 19446 for hemoglobin

1. Neurology - Clinical trials

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

2. Lipodystrophy syndromes: New treatment, newer questions - Mayo Clinic

   ... hemoglobin A1C, a 60 percent reduction in serum triglycerides and hepatic transaminases, and 28 percent reduction in liver volume, besides improvements in ...

3. A Study Of BMS-986340 In Combination With Nivolumab, Gemcitabine And Nab-paclitaxel In The First Line Setting Of Metastatic Pancreatic Adenocarcinoma - Mayo Clinic

   Hemoglobin ≥9.0 g/dL (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration). White blood cells (WBC) ...

4. VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM - Mayo Clinic

   Hemoglobin (HgB) ≥9 g/dL. Platelets ≥100,000/μL (≥150,000/μL, if within 12 weeks of prior nitrosourea treatment). Serum creatinine ≤1.5 x upper limit of ...

5. Panobinostat and Everolimus in Treating Patients with Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma - Mayo Clinic

   Quantitative immunoglobulin (Ig)M monoclonal protein > 1,000 mg/dL. Absolute neutrophil count (ANC) ≥ 1000/uL; Hemoglobin (Hgb) ≥ 9 g/dl; Platelets (PLT) ...

6. Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction - Mayo Clinic

   Hemoglobin ≥ 9 g/dL (transfusions and/or erythropoietin are permitted); Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L (or ...

7. A Study to Compare Administering Olaparib Concurrently With Radiotherapy vs. Radiotherapy Alone in Treating Patients With Inflammatory Breast Cancer - Mayo Clinic

   Hemoglobin >= 9.0 g/dL (after transfusion if required and within 28 days prior to registration). Patients must have adequate renal function as evidenced by ...

8. STI-3031 Through Sofusa DoseConnect for Treatment of Intransit Melanoma - Mayo Clinic

   Hemoglobin ≥ 8.0 g/dL;; Absolute neutrophil count (ANC) ≥ 1500/mm^3;; Platelet count ≥ 75,000/mm^3;; Total bilirubin ≤ 1.5 × ULN;; Alanine aminotransferase ...

9. A Study To Evaluate The Effectiveness, Safety, And Tolerability Of BOS-589 In The Treatment Of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) - Mayo Clinic

   Hemoglobin A1c level ≥ 8.0% or a confirmed fasting plasma glucose level ≥ 180 mg/dL. Confirmed alanine aminotransferase (ALT) upper limit of normal (ULN) ...

10. Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia - Mayo Clinic

    ... hemoglobin (Hb) of < 9 g/dL prior to first dose of H3B-8800 (RVT-2001). Subjects who are RBC transfusion-dependent must also have failed erythropoiesis ...